Easy dissolvable oral strips for preventing latent tuberculosis
Oral Dissolvable Strips (ODS) as new pediatric and adult delivery mode of therapy for latent tuberculosis
['FUNDING_SBIR_2'] · OAK THERAPEUTICS, INC. · NIH-11253372
This project is developing thin oral strips that dissolve in the mouth to deliver TB prevention medicine for children and adults with latent tuberculosis.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OAK THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (Lawrence, UNITED STATES) |
| Trial ID | NIH-11253372 on ClinicalTrials.gov |
What this research studies
From a patient perspective, the team is making small, dissolvable oral strips containing the main TB preventive drugs so people won't need to swallow large tablets. The strips aim to improve taste, allow weight-based dosing for children, and be easier for caregivers to give infants. Developers will optimize formulations for stability and accurate dosing and perform laboratory and bioequivalence testing compared to current tablet forms. If needed, the program could include early human dosing or bridging studies to confirm the strips deliver the right drug levels.
Who could benefit from this research
Good fit: People with latent tuberculosis infection, including children who have trouble swallowing pills and adults seeking easier preventive therapy, would be the ideal candidates for this approach.
Not a fit: Patients with active TB disease, people allergic to rifapentine or isoniazid, or those already well served by current tablet regimens may not benefit from these strips.
Why it matters
Potential benefit: If successful, these strips could make TB prevention treatment simpler, safer, and more likely to be completed, reducing future active TB cases.
How similar studies have performed: Orally dissolving strips and films have worked well for other pediatric medicines, but applying this approach to TB drugs is relatively new and still being proven.
Where this research is happening
Lawrence, UNITED STATES
- OAK THERAPEUTICS, INC. — Lawrence, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MALISKI, EDWARD G — OAK THERAPEUTICS, INC.
- Study coordinator: MALISKI, EDWARD G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.